Drug intelligence / Profile preview

AdNRGM

Development stage
Phase 1
Lead developer
Zensun
Modality
Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration
Intracoronary
01

Overview

AdNRGM is an investigational gene therapy consisting of a recombinant adenoviral vector (typically serotype 5) encoding the epidermal growth factor (EGF)-like domain of human neuregulin-1 (NRG1). Developed by Zensun (Shanghai) Sci & Tech, it is designed for the treatment of chronic heart failure. The mechanism involves the local expression of NRG1, which binds to and activates ErbB4 receptors on cardiomyocytes, subsequently inducing heterodimerization with ErbB2. This activation triggers downstream signaling pathways, including PI3K/Akt and MAPK, which promote cardiomyocyte survival, improve sarcomere organization, and enhance cardiac contractility. By delivering the NRG1 gene directly to the cardiac environment, AdNRGM aims to provide a sustained therapeutic effect and overcome the short half-life limitations associated with recombinant protein administration.

Other names
Adenoviral Neuregulin-1Ad-NRG1Ad-NRG-1Ad-NRG 1
02

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)

Beyond the preview

Go deeper on AdNRGM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdNRGM.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call